ACTOv clinical trial

[Cardiff05]

HiWonder if anyone is taking part in the ACTOv, trial for patients with high-grade serous and endometrioid ovarian cancer.

My wife is facing a reoccurrence and further carboplatin treatment

[candyapplegrey]

Hi there, I'm facing a second recurrence. I wish I could help you. I have clear cell and endometrioid G3 cancer. Do you know where the trials are taking place? You could ask Ovacome team or Macmillan perhaps. Sorry not to be able to help more. x

[Cardiff05 in reply to candyapplegrey]

Hi

I'm sorry I could have been clearer in my original post! I've copied a summary of the trial but I'm unsure what the next step is!

We're meeting with my wife's oncologist tomorrow and shall run it past him.

Adaptive chemotherapy does seem to make sense given the potential for developing resistance.

Hope this helps.

(Adaptive ChemoTherapy in Ovarian cancer) clinical trial, which is the UK’s first trial to test adaptive therapy and the first global experience testing adaptive therapy in ovarian cancer patients.

ACTOv, which will be conducted by the CR UK & UCL Cancer Trials Centre, will recruit 80 patients with high-grade serous and endometrioid ovarian cancer (HGOC; the most common type of ovarian cancer) across nine hospitals in the UK (including St Bartholomew’s Hospital and University College Hospital in London). Half of the patients will receive six cycles of the same standard dose of a chemotherapy called carboplatin, while the other half will receive an adaptive therapy regimen of carboplatin.

In the adaptive therapy group, the treatment dose for each cycle will be guided by the level of a protein found in the blood of ovarian cancer patients, called CA125, which is a marker of tumour size. After each cycle, patients will have a blood test and if their tumour has shrunk (i.e. the level of CA125 has decreased), the carboplatin dose will be reduced and if their tumour has grown (i.e. the level of CA125 has risen), the carboplatin dose administered will be increased. By adjusting the chemotherapy dose in this way, the team hopes to preserve sensitivity to carboplatin in the cancer patients, while reducing the treatment dose required and associated toxicities.

[candyapplegrey in reply to Cardiff05]

Thanks so much for all that information. Did you find anyone who was on the trial?

[Cardiff05 in reply to candyapplegrey]

Hope it's of some use, nonetheless I know there's several other trials out there .Oncologist has decided to continue with current treatment c/o slow growth ,low volume and delay using platinum chemotherapy until later.

Unfortunately Hb dropped this weekend plus possibly an infection so currently in hospital receiving transfusion.

But as she says .....' she'll be back"

Good luck